$CADL News

Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25

Candel Therapeutics Appoints Maria Ostrovsky as General Counsel

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.

CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics Announces Immunological Biomarker Data From Ongoing Phase 2 Prtk05 Trial In Patients With Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics Presents New Biomarker Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4

B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present at September Investor Conferences

Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?

Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

B of A Securities Maintains Neutral on Candel Therapeutics, Raises Price Target to $12

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4